Conformis (NASDAQ:CFMS) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Conformis (NASDAQ:CFMS – Get Free Report) in a note issued to investors on Friday. The brokerage set a “hold” rating on the medical instruments supplier’s stock.

Separately, Oppenheimer downgraded Conformis from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 9th.

Get Conformis alerts:

Conformis Stock Performance

NASDAQ:CFMS opened at $2.22 on Friday. Conformis has a twelve month low of $1.05 and a twelve month high of $9.43. The company has a current ratio of 5.71, a quick ratio of 4.06 and a debt-to-equity ratio of 0.46. The company has a 50-day moving average of $1.48 and a 200-day moving average of $1.88. The firm has a market cap of $16.60 million, a price-to-earnings ratio of -0.36 and a beta of 1.39.

Conformis (NASDAQ:CFMS – Get Free Report) last posted its quarterly earnings data on Monday, May 8th. The medical instruments supplier reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.56) by $0.24. Conformis had a negative net margin of 74.18% and a negative return on equity of 75.43%. The company had revenue of $12.84 million during the quarter, compared to analyst estimates of $12.54 million. Analysts forecast that Conformis will post -5.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS Group AG increased its position in Conformis by 24.7% in the first quarter. UBS Group AG now owns 115,831 shares of the medical instruments supplier’s stock worth $186,000 after purchasing an additional 22,911 shares during the period. Dimensional Fund Advisors LP bought a new stake in Conformis during the 4th quarter worth approximately $91,000. Bank of New York Mellon Corp boosted its holdings in shares of Conformis by 2.3% in the third quarter. Bank of New York Mellon Corp now owns 368,020 shares of the medical instruments supplier’s stock valued at $71,000 after buying an additional 8,191 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Conformis by 4.1% in the third quarter. Renaissance Technologies LLC now owns 4,763,691 shares of the medical instruments supplier’s stock valued at $911,000 after buying an additional 188,200 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Conformis in the second quarter valued at approximately $84,000. 25.13% of the stock is owned by institutional investors.

Conformis Company Profile

(Get Free Report)

Conformis, Inc, a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products.

Featured Articles

• Five stocks we like better than Conformis
• Delta Takes Flight: Double-Digit Upside In Sight
• Generac Powers Up as Summer Temperatures Rise
• 3 Reasons Why Rivian Can Continue To Surge Higher
• Despite Breaking Higher, Analysts Remain Cautious HP Inc.
• PepsiCo Can Soar To New Highs In The 2nd Half

Receive News & Ratings for Conformis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conformis and related companies with MarketBeat.com's FREE daily email newsletter.